Intarcia

Boston, United States Founded: 1995 • Age: 31 yrs Unicorn
Osmotic mini-pumps for subcutaneous drug delivery are developed.

About Intarcia

Intarcia is a Healthcare company based in Boston (United States) founded in 1995. Osmotic mini-pumps for subcutaneous drug delivery are developed. Intarcia has raised $1.89 billion across 22 funding rounds from investors including Fidelity Investments, SVB and Gates. The company has 68 employees. Intarcia was last valued at $3.5 billion in December 2020. Its focus areas include Life Sciences, Diabetes, Drugs and Drug Delivery. Its legal entity is INTARCIA THERAPEUTICS, INC. Its competitors include Sana Biotechnology, Semma Therapeutics and Rezolute; 2 of its 3 listed competitors have raised funding.

Company details

Intarcia Therapeutics was founded in 1995 in Boston, United States, within the biotechnology sector. A platform technology for drug delivery is provided, featuring subcutaneous osmotic mini-pumps. These devices are implanted under the skin and filled with the required drug volume. Extracellular fluid water enters the pump, generating osmotic pressure that propels a piston to release the drug steadily over time. Operations focus on this implantation-based delivery method.

  • Headquarters Boston, United States
  • Employees 68
  • Stage Unicorn
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website intarcia.com
  • Social LinkedIn X
  • Legal Name Intarcia Therapeutics, Inc.
Key Metrics
  • Total Equity Funding
    $1.89B (USD)

    in 22 rounds

  • Latest Funding Round
    $198.5M (USD), Series J

    Jan 2020

  • Investors
  • Employee Count
    68

Funding Insights of Intarcia

Intarcia has successfully raised a total of $1.89B across 22 strategic funding rounds. The most recent funding activity was a Series J round of $198.5 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $1.89B
  • Total Rounds 22
  • Last Round Series J β€” $198.5M
  • First Round $38M

    (Sep 2000)

  • Investors Count 43

Latest 10 of 22 funding rounds of Intarcia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2020$198.5MSeries J––
–
Jan 2018$8MSeries J–Ascent Venture Partners
Aug 2017$524.6MSeries J–Gates Foundation
–
Jan 2017$50MSeries J–Gates Foundation
–
Jan 2017$90MGrant––
May 2016$75MDebt – Conventional––
Jun 2015$300MSeries J$5.5B–
–
Apr 2014$200MSeries I–RA Capital Management
Nov 2012$50MDebt – Conventional––
Nov 2012$160MSeries H–New Leaf Venture Partners, Venrock
Valuation history
DateValuationStage
Jun 2015$5.5Bβ€’β€’β€’β€’β€’β€’β€’β€’
Premium access

Full valuation and stage history of Intarcia

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $3.5B (Dec 2020). 43 investors in total: 43 institutional.

Investors in Intarcia

Intarcia has secured backing from 43 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, SVB and Gates.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
US focused early-stage VC firm
ascentvp.comBedford, United States
Venture capital investments in early stage B2B software and academic research startups.
osagepartners.com
nxtventures.com
Private debt funds are managed across multiple sectors.
2008midcapfinancial.comBethesda, United States
Multiple investment strategies are pursued by this hedge fund.
1986faralloncapital.comSan Francisco, United States
Multi-stage investment firm invests in healthcare and life sciences companies
foresitecapital.comNew York, United States
ESG investments are managed by this venture capital firm.
1964alger.comNew York, United States
Stage-agnostic investments in US life sciences are managed.
2005nlvpartners.comNew York, United States
PE firm backed by quilvest group
quilvestprivateequity.comLas Condes, Chile
Venture capital investments are offered to startups by NEA.
nea.comMenlo Park, United States
Premium access

Investor details for Intarcia

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Intarcia

10 people are tracked at Intarcia (5 in leadership, 5 in team); the tracked headcount is 68.

NameRoleGroup
Karina N.
Executive Director, Corporate ControllerLeadership
Kesete Kifle
Director, MSAT Corporate ValidationLeadership
Habeeb O.
Director, Clinical Data ManagerLeadership
Bing Yang
Vice President, Pharmaceutical SciencesLeadership
Debra Platek
Senior Director, Device DesignLeadership
Malachy O'Dornan
Senior Project ManagerTeam
Louise Lu
Sr. Data ReviewerTeam
Sandra Miyahara
Environmental, Health, and SafetyTeam
Cristiana Eftimie
Senior ScientistTeam
Marivic Matias
Quality Control Data SpecialistTeam
Premium access

Complete people profiles for Intarcia

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Intarcia

4 dated milestones of Intarcia across 25 years, from founding to its latest funding, stage changes and deals.

  1. Founded Intarcia is founded.
  2. Funding First funding round of $38.0M.
  3. Milestone Reaches Unicorn status.
  4. Funding Latest funding round, Series J, of $198.5M.

Competitors of Intarcia

Intarcia has 3 listed competitors in our database, 2 of them funded. They include Sana Biotechnology, Semma Therapeutics and Rezolute.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
sana.com2018Seattle, United States$821M328
Genetically engineered cell therapies are developed for multiple disorders.
semma-tx.com2015Cambridge, United States$158M58
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
rezolutebio.com2012Denver, United States51
Therapies for metabolic and orphan diseases are developed by Rezolute.
Premium access

Detailed competitors of Intarcia

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Intarcia

Websites that share an audience with Intarcia (intarcia.com).

Similar websites

Websites whose visitors overlap most with Intarcia. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
edgetherapeutics.com
100%
View details
addextherapeutics.com
97%
3.3K#7,605,013View details
argostherapeutics.com
96%
View details
g1therapeutics.com
96%
2.8K#6,603,375View details
abeonatherapeutics.com
95%
8K#2,941,685View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 13 similar websites and full traffic analytics for Intarcia

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 13 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Diabetes

3 companies that operate in the same segment as Intarcia (Diabetes) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of devices for continuous glucose monitoring and manual insulin delivery
2008San Diego, California, United StatesUSD 100.73 MUSD 1.02 B2,650
Wearable glucose monitoring patches are provided for real-time data tracking.
1999San Diego, California, United StatesUSD 52.5 MUSD 4.66 B10,300
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Intarcia

Premium access

Complete news archive for Intarcia

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Intarcia

Intarcia was founded in 1995 and raised its 1st funding round 5 years after it was founded.

Intarcia is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Intarcia is a funded company, having raised a total of $1.89B across 22 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $50M, raised on Sep 2000.

Intarcia has 68 employees.

Intarcia Therapeutics was founded in 1995 in Boston, United States, within the biotechnology sector. A platform technology for drug delivery is provided, featuring subcutaneous osmotic mini-pumps. These devices are implanted under the skin and filled with the required drug volume. Extracellular fluid water enters the pump, generating osmotic pressure that propels a piston to release the drug steadily over time. Operations focus on this implantation-based delivery method.

Intarcia's top competitors include Sana Biotechnology, Semma Therapeutics and Rezolute.

Intarcia has 43 investors. Key investors include Fidelity Investments, SVB, Gates, New Leaf Venture Partners, and Franklin Templeton.

The valuation of Intarcia is $3.5B as of Dec 2020.

Intarcia operates through Intarcia Therapeutics, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available